Mizuho upgraded shares of Amedisys Inc (NASDAQ:AMED) from a neutral rating to a buy rating in a research report report published on Thursday morning.

A number of other research analysts also recently commented on AMED. BidaskClub downgraded shares of Amedisys from a strong-buy rating to a buy rating in a research note on Wednesday, July 12th. Bank of America Corporation started coverage on shares of Amedisys in a research note on Monday, August 21st. They set a neutral rating and a $55.00 price objective on the stock. Oppenheimer Holdings, Inc. reiterated a buy rating and set a $60.00 price objective on shares of Amedisys in a research note on Friday, September 15th. Robert W. Baird reiterated a hold rating and set a $50.00 price objective on shares of Amedisys in a research note on Wednesday, October 4th. Finally, SunTrust Banks, Inc. reiterated a buy rating and set a $60.00 price objective on shares of Amedisys in a research note on Monday, October 9th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $56.10.

Shares of Amedisys (AMED) traded up $1.65 during mid-day trading on Thursday, hitting $54.80. 514,340 shares of the stock traded hands, compared to its average volume of 467,569. The stock has a market capitalization of $1,855.64, a P/E ratio of 28.99, a PEG ratio of 1.34 and a beta of 0.68. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.17. Amedisys has a fifty-two week low of $34.58 and a fifty-two week high of $65.91.

TRADEMARK VIOLATION NOTICE: “Amedisys Inc (AMED) Raised to “Buy” at Mizuho” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/amedisys-inc-amed-raised-to-buy-at-mizuho/1681212.html.

In other Amedisys news, insider David B. Pearce sold 1,000 shares of the stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares of the company’s stock, valued at $524,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of AMED. UBS Asset Management Americas Inc. raised its holdings in shares of Amedisys by 140.0% during the first quarter. UBS Asset Management Americas Inc. now owns 11,760 shares of the health services provider’s stock worth $601,000 after purchasing an additional 6,861 shares during the period. Teachers Advisors LLC raised its holdings in shares of Amedisys by 1.5% during the first quarter. Teachers Advisors LLC now owns 77,481 shares of the health services provider’s stock worth $3,959,000 after purchasing an additional 1,144 shares during the period. Legal & General Group Plc raised its holdings in shares of Amedisys by 3.6% during the first quarter. Legal & General Group Plc now owns 51,887 shares of the health services provider’s stock worth $2,652,000 after purchasing an additional 1,825 shares during the period. Thrivent Financial For Lutherans raised its holdings in shares of Amedisys by 3.8% during the first quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock worth $802,000 after purchasing an additional 570 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Amedisys by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock worth $121,067,000 after purchasing an additional 63,238 shares during the period. 96.86% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.